Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE STEMI ONE
NL-OMON59397Phase 4Recruiting
- Sponsor
- Research Cardiologen Rotterdam Zuid
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prasugrel in acute ST-segment elevation myocardial infarction (STEMI) (4 arms), sponsored by Research Cardiologen Rotterdam Zuid. Primary endpoints: Net Adverse Clinical Events and Post-procedural Minimal Stent Area. Started Aug 2024; status: recruiting.
02
Drugs
prasugrel
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NL-OMON59397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59397.